Introduction
============

Gastric carcinoma (GC), a serious threat to human health, is one of the most common malignancies in China, and its incidence and deaths rank first in the digestive system in 2015 ([@b1-ol-0-0-8941]). The occurrence of GC involves a complex pathological process associated with polygenic interactions and multi-phase evolution ([@b2-ol-0-0-8941]). The majority of patients experience the typical stages of normal gastric mucosa, chronic atrophic gastritis, precancerous lesions (atypical hyperplasia of gastric mucosa and intestinal metaplasia), early stages of gastric cancer, and advanced stage of disease ([@b3-ol-0-0-8941]). However, at present, the molecular mechanisms underlying the occurrence of GC remain unclear.

The cross-talk that exists between tumor cells and the microenvironment serves an important function in the occurrence and development of tumors ([@b4-ol-0-0-8941]). Tumor cells adapt to their microenvironment and exhibit corresponding biological characteristics. The tumor microenvironment refers to the internal environment in which the tumor grows, which is primarily composed of various interstitial cells, blood vessels, nerves, interstitial fluid and a small number of leucocytes ([@b5-ol-0-0-8941]). Tumor cells are able to induce mesenchymal cells to produce a variety of cytokines and growth factors that promote tumorigenesis and development ([@b6-ol-0-0-8941]). According to previous studies ([@b7-ol-0-0-8941]), it is possible to target the formation mechanism of the tumor microenvironment in order to prevent the proliferation and metastasis of tumor cells. Knowledge of the interaction between the microenvironment and tumor cells is expected to provide a rich theoretical basis for the treatment of tumors. The aim of the present study was to elucidate the molecular mechanisms underlying the occurrence of GC by analyzing the protein interactions in gastric mucosal atypical hyperplasia.

Materials and methods
=====================

### Tissue samples

Matching specimens, including 20 cases of normal gastric mucosa (NGM) tissue and gastric mucosa atypical hyperplasia (GMAH) tissue, were collected from The First Affiliated Hospital of University of South China between September 2016 and June 2017. The Cancer Research Institute of University of South China and The First Affiliated Hospital of University of South China are cooperative relations. Researchers from Cancer Research Institute are permitted to travel to the hospital and collect specimens with the permission of the medical ethics committee of University of South China. Specimens were collected from the stomach within 5 min of resection, and the gastric mucosal surface was washed with physiological saline prior to and following the incision. The samples were immediately frozen in liquid nitrogen and stored at −80°C. [Table I](#tI-ol-0-0-8941){ref-type="table"} presented the clinical data including tumor stage determined by the eighth edition AJCC cancer staging manual ([@b8-ol-0-0-8941]) of 20 patients with GC. Two senior professional pathologists from Cancer Research Institute of University of South China were asked to independently diagnose the collected tissue samples without knowing any clinical or pathological data.

### Ethics statement

The human GC tissue samples were collected from The First Affiliated Hospital of University of South China according to the institutional and governmental guidelines. All patients involved in the present study provided written informed consent, and the present study was approved by the medical ethics committee of University of South China (Hengyang, China).

### Preparation and staining of frozen sections

The tissue samples were removed from liquid nitrogen and placed on a cryostat device carrier (Leica Biosystems GmbH, Wetzlar, Germany). Following the addition of optimal cutting temperature compound (OCT) embedding agent (Leica Microsystems GmbH), the samples were frozen at −25°C for 20 min. Next, the samples were immobilized to the platform of the cryostat device, and frozen sections were made at a thickness of 8 µm. The frozen sections were affixed to film slides (Leica Microsystems GmbH) pretreated with ultraviolet (UV) light. Finally, the slides were fixed with 75% ethanol at 4°C for 60 sec, stained with 0.5% methyl green (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 4°C for 30 sec and discolored with 95% ethanol at 4°C for 5 sec.

### Laser capture microdissection (LCM)

The frozen tissue sections stained with methyl green were placed on an LCM apparatus (Leica LMD6, Leica Microsystems GmbH) platform. The target tissue was outlined on the display, and the laser automatically cut the target tissue in the slice. Dissolved one tablet of protease inhibitor cocktail tablets (Roche Diagnostics, Basel, Switzerland) in 50 ml ultrapure water to prepare 5% working solutions. The tissues were collected in a tube containing 2--3 µl protease inhibitor working solutions and were frozen at −80°C for later use.

### Protein extraction and isobaric tags for relative and absolute quantitation (iTRAQ) isotope labeling

The mesenchyma of the NGM and GMAH tissues were extracted using a lysis buffer (10 mM PMSF, 65 mM dithiothreitol, 7 M urea and 2 M thiourea) (GE Healthcare Life Sciences, Little Chalfont, UK) and centrifuged at 4°C, 12,000 × g for 30 min. The supernatant included the total proteins of the NGM and GMAH mesenchyma. The total proteins were extracted and quantified using a bicinchonic acid protein assay kit (Beyotime Institute of Biotechnology, Shanghai, China), according to the manufacturer\'s protocol. The total proteins of the NGM mesenchyma were labeled with iTRAQ reagent 114; total proteins of the GMAH mesenchyma were labeled with iTRAQ reagent 118 (both Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s protocol. A total of 100 µl ultrapure water was used to end the reaction. All protein samples were homogenized and lyophilized, and then the samples were dissolved in deionized water containing 0.1% formic acid (FA; Tedia Company, Fairfield, OH, USA). The marked samples were eluted twice with Sep-Pak C~18~ 1 cc Vac cartridges (Waters Corporation, Milford, MA, USA) with deionized water containing 0.1% FA and then once with 50% acetonitrile (ACN) (Thermo Fisher Scientific, Inc.) containing 0.1% FA. The cleaning solution was collected and lyophilized.

### Identification of differentially expressed proteins

The samples marked with iTRAQ were dissolved in 1 ml strong cation-exchange (SCX) buffer \[25% (v/v) ACN and 10 mM KH~2~PO~4~, pH 2.6\] for SCX separation. The two samples containing mesenchymal proteins of NGM and GMAH were mixed and loaded into a polysulfoethyl column and segregated using a 20AD high performance liquid chromatography (HPLC) system (Shimadzu Corporation, Kyoto, Japan) with the following conditions: i) 10 mM KH~2~PO~4~ and 25% ACN, pH 2.6; ii) 10 mM KH~2~PO~4~, 350 mM KCl and 25% ACN, pH 2.6. The following settings were used: UV detection wavelength: 214/280 nm; flow rate: 200 µl/min for 60 min; salt gradient: from 5% i) at 5 min to 25% ii) at 40 min. Next, the products were concentrated by vacuum centrifugation for reverse-phase HPLC-mass spectrometry (MS) analysis. The samples were dissolved in 50 µl 5% ACN containing 0.1% FA and were loaded into a Zorbax 300SB-C~18~ column (Agilent Technologies, Inc., Santa Clara, CA, USA). The conditions were as follows: i) 5% ACN, 0.1% FA; ii) 95% ACN, 0.1% FA. Flow rate: 300 nl/min for 90 min. Salt gradient: from 5% i) at 5 min to 35% ii) at 70 min. The data were analyzed using QSTAR-XL (Applied Biosystems; Thermo Fisher Scientific, Inc.) and tandem MS (MS/MS). Finally, the IPI human database (version 3.45; URL: <http://www.ebi.ac.uk/IPI>) was searched for protein information, and the confidence level was set to be \>95%, and the ion peak areas of m/z 114 and 118 were integrated to perform relative quantitative analysis of proteins.

### Western blot analysis

The total NGM and GMAH mesenchymal proteins were mixed with 5X loading buffer (Beyotime Institute of Biotechnology) and boiled for 5 min. The proteins had been quantified using a bicinchonic acid protein assay kit (Beyotime Institute of Biotechnology). Next, the samples were separated using 10% gradient SDS-PAGE gels at 30 µg per lane and transferred onto PVDF membranes (Merck KGaA). The membranes were blotted with 5% fat-free milk suspended in TBST at room temperature for 1 h, incubated at 4°C overnight with S100 calcium-binding protein A6 (S100A6) antibody (1:1,000) (sc-53950; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and superoxide dismutase 3 (SOD3) antibody (1:1,000) (sc-58427; Santa Cruz Biotechnology, Inc.), washed and then incubated with goat anti-mouse IgG-HRP (1:2,000) (sc-2005; Santa Cruz Biotechnology, Inc.) at room temperature for 2 h. Detection of immunoreactivity was achieved using enhanced chemiluminescence (GE Healthcare Life Sciences).

### Immunohistochemistry

The present study used S-P immunohistochemical staining kits (MXB Company, Fujian Province, China; URL: <http://www.maxim.com.cn/>). The NGM and GMAH tissues were fixed with 10% formalin and embedded in paraffin. The expression of S100A6 and SOD3 proteins were detected according to the manufacturer\'s protocol. Briefly, 4-µm-thick sections were prepared and mounted on poly-L-lysine-coated glass slides, air-dried, deparaffinized with xylene and rehydrated in a descending ethanol series. Following microwave treatment for 20 min, endogenous peroxidase activity was suppressed using 0.3% hydrogen peroxide. The sections were treated with 5% normal goat serum (SL038) (Solarbio Life Sciences, Tongzhou Dist. Beijing, China) at room temperature for 15 min to block non-specific binding. The sections were incubated with anti-S100A6 (1:100) or anti-SOD3 (1:100) antibody overnight at 4°C, and then incubated with goat anti-mouse IgG-FITC (1:200) (sc-2010; Santa Cruz Biotechnology, Inc.) at room temperature for 60 min followed by horseradish peroxidase-labeled streptavidin for 5 min at room temperature. The sections were counterstained with 0.1% hematoxylin at room temperature for 30 sec. The tissue staining was observed under a light microscope at a magnification of ×40. The final immunoreactive score was based on protein staining intensity and the percentage of positive cells. Staining intensity was defined as 1 (negative), 2 (yellow) and 3 (brown). The percentage of positive cells was defined as 1 (\<10% positive cells), 2 (11--50% positive cells) and 3 (\>50% positive cells). The final immunoreactive score was calculated as: Staining intensity × percentage of positive cells. The classification of the final score was defined as - (score 1), + (score 2--4) and +++ (score \>4).

### Protein signaling pathways and interaction analysis

Visant software (version 3.91; URL: <http://visant.bu.edu>) was used to analyze the interactions between proteins. Additionally, the network of direct interactions between proteins was analyzed. The Clue Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of protein signaling pathways was performed using Cytoscape software (version 2.8.2; URL: <http://www.cytoscape.org>). GO_BP, GO_CC and GO_MF analyses were executed with David Functional Annotation (URL: <http://david.abcc.ncifcrf.gov>).

### Statistical analysis

The data are reported as the mean ± standard deviation. Statistical analysis was performed using SPSS statistical package (version 18.0; SPSS, Inc., Chicago, IL, USA) as follows: Comparison between individual subgroups was performed using the Mann-Whitney U test, and correlation analysis between groups was performed using Spearman\'s rank correlation test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Purified mesenchyma of NGM and GMAH tissues

The NGM and GMAH tissues were obtained from fresh specimens of GC following surgical resection, and all tissues were confirmed by pathology. The mesenchyma of NGM and GMAH tissues were purified by LCM ([Fig. 1](#f1-ol-0-0-8941){ref-type="fig"}). The purity of objective groups was \>95%.

### Identification of differentially expressed proteins

The NGM and GMAH mesenchyma proteins were divided into solutions and marked using different isotopic iTRAQ. Next, the NGM and GMAH proteins were separated using a 20AD HPLC system and identified using QSTAR-XL MS/MS. A total of 165 differentially expressed proteins between the NGM and GMAH mesenchyma were identified ([Table II](#tII-ol-0-0-8941){ref-type="table"}). The G/N value (NGM/GMAH tissue) was determined as the mean protein expression level. In total, 99 proteins (G/N\>1.5) were identified to be upregulated and 66 proteins (G/N\<0.667) were identified to be downregulated in the GMAH mesenchyma. The expression levels of the S100A6 and SOD3 proteins were different in the mesenchyma of the NGM and GMAH tissues, and were associated with tumorigenesis in previous studies ([@b9-ol-0-0-8941],[@b10-ol-0-0-8941]). [Fig. 2](#f2-ol-0-0-8941){ref-type="fig"} presents the MS results and the quantification of the S100A6 ([Fig. 2A](#f2-ol-0-0-8941){ref-type="fig"}) and SOD3 proteins ([Fig. 2B](#f2-ol-0-0-8941){ref-type="fig"}).

### S100A6 is upregulated and SOD3 is downregulated in GMAH mesenchymal tissue

The 20 samples of NGM and GMAH tissues were collected and purified. Next, the tissues were sectioned. The expression levels of the S100A6 and SOD3 proteins in NGM and GMAH mesenchyma were detected using western blotting and immunohistochemistry. The result of western blotting indicated that the S100A6 protein was upregulated, but that the SOD3 protein was significantly downregulated in the GMAH mesenchyma when compared with the NGM tissue (P\<0.01; [Fig. 3A](#f3-ol-0-0-8941){ref-type="fig"}). Immunohistochemistry analysis demonstrated that S100A6 and SOD3 proteins were expressed in the mesenchyma of NGM and GMAH tissues; however, the staining intensity and expression levels of the S100A6 protein in the GMAH tissue were increased compared with those in the NGM tissue. The expression of the SOD3 protein was the opposite ([Fig. 3B and C](#f3-ol-0-0-8941){ref-type="fig"}). Therefore, the S100A6 and SOD3 expression levels were significantly different between the NGM and GMAH tissues (P\<0.05; [Table III](#tIII-ol-0-0-8941){ref-type="table"}). These results were consistent with the results of quantitative proteomics in the present study ([Table II](#tII-ol-0-0-8941){ref-type="table"}).

### Interaction of differentially expressed proteins and relevant signaling pathways analysis

The interaction between 165 differentially expressed proteins in GMAH were analyzed using Visant software. It was identified that 140 proteins acted as network nodes and interacted with each other. The results of KEGG signal pathway analysis demonstrated that the 165 proteins were involved in a number of tumor signaling pathways, including the p53, mitogen-activated protein kinase (MAPK), cell cycle, and apoptosis signaling pathways ([Fig. 4](#f4-ol-0-0-8941){ref-type="fig"}). Next, the biological functions of the 165 proteins were analyzed with the David tool, which indicated that the proteins were involved in cell growth, proliferation, apoptosis and the humoral immune response (results not shown).

Discussion
==========

The microenvironment is composed of stromal cells, immune cells and cytokines, and the tumor microenvironment has been proven to determine the biological behavior of tumor cells ([@b11-ol-0-0-8941],[@b12-ol-0-0-8941]). It is hypothesized that the interactions of protease, cytokines and receptors in the tumor microenvironment affect the osmotic pressure and metabolism of the tumor, which may result in immune escape and neoplasia ([@b13-ol-0-0-8941],[@b14-ol-0-0-8941]). It is important to monitor cell behavior and prevent cancer by understanding changes in the microenvironment, which serve important functions in tumor occurrence and development ([@b4-ol-0-0-8941]). In the present study, 165 proteins that were differentially expressed between the NGM and GMAH tissue microenvironments were screened. These proteins were demonstrated to be involved in signaling pathways associated with cancer, including the MAPK, VEGF and p53 signaling pathways, suggesting that these proteins may regulate cell growth, proliferation, apoptosis and the humoral immune response. However, the interaction network should be further characterized in follow-up studies. In the present study, the expression of S100A6 and SOD3 was analyzed by western blotting and immunohistochemical staining techniques, and was identified to be significantly different and associated with tumorigenesis. These results were consistent with the results of quantitative proteomics in the present study.

S100A6 is a member of the S100 protein family ([@b15-ol-0-0-8941]). S100A6 has a number of biological functions, including participating in the degradation and ubiquitination of β-catenin, promoting apoptosis, interacting with extracellular matrix proteins, enhancing cell metabolism and skeleton depolymerization, participating in endocytosis and exocytosis, adjusting enzyme activity, inhibiting protein kinase C-mediated phosphorylation and participating in gene transcription ([@b16-ol-0-0-8941],[@b17-ol-0-0-8941]). A number of studies have demonstrated that S100A6 is also associated with the occurrence and development of tumors and is upregulated in several tumors, including ovarian cancer, colorectal cancer, pancreatic cancer, liver cancer, malignant melanoma and osteosarcoma ([@b18-ol-0-0-8941],[@b19-ol-0-0-8941]). According to the results of the present study, S100A6 is upregulated in the GMAH stroma. This protein may contribute to the malignant transformation of epithelial cells of gastric mucosa and promote cell invasion and metastasis. The S100A6 protein may be a potential biomarker for monitoring malignant cell transformation.

Mammalian SODs have three subtypes, namely the cytoplasmic SOD (CuZnSOD or SOD1), mitochondrial SOD (MnSOD or SOD2) and extracellular SOD (EC-SOD or SOD3) ([@b20-ol-0-0-8941]). SOD3 serves an important function in maintaining the oxidation balance that prevents nuclear DNA and protein oxidative damage in the extracellular matrix and nucleus ([@b21-ol-0-0-8941]). Previous studies have identified that the level of SOD3 was decreased in a variety of tumors, including lung, breast and thyroid cancer, and renal cell carcinoma ([@b10-ol-0-0-8941],[@b22-ol-0-0-8941]). SOD3 is widely expressed in normal tissues; low or no expression of SOD3 causes an imbalance in the extracellular redox environment and cancer occurs more frequently in an imbalanced environment ([@b23-ol-0-0-8941]). Therefore, a low or no expression of SOD3 may be a risk factor for malignant cell transformation ([@b24-ol-0-0-8941]). The results of the present study demonstrated that SOD3 was downregulated in GMAH stroma, which resulted in DNA damage in gastric mucosa epithelial cells and GC. Therefore, the early detection of SOD3 may predict the occurrence of GC.

As the tumor microenvironment serves a critical function in GC occurrence and development, it important to identify the proteins present in the GMAH microenvironment. The present study identified a total of 165 differentially expressed proteins in GMAH stroma. These data will further clarify the molecular mechanisms of GC occurrence as well as potentially serving as prognostic markers for the early detection and diagnosis of GC.
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![Purification of mesenchyma of NGM and GMAH tissues by LCM. The purified mesenchyma of NGM and GMAH tissues prior to and following LCM are indicated in the area surrounded by the closed line at a magnification of ×10. NGM, normal gastric mucosa; GMAH, gastric mucosal atypical hyperplasia; LCM, laser-capture microdissection.](ol-16-02-2355-g00){#f1-ol-0-0-8941}

![Mass spectrometry and quantification of S100A6 and SOD3 proteins. (A) Top: The peptide mass fingerprint and sequence LQDAEIAR allowed the identification of S100A6. Bottom: The released iTRAQ reporter ions provided the relative quantification of S100A6 from the mesenchyma of NGM and GMAH tissues evaluated. (B) Top: The peptide mass fingerprint and sequence VTGVVLFR allowed the identification of SOD3. Bottom: The released iTRAQ reporter ions provide the relative quantification of SOD3 from the two tissues evaluated. S100A6, S100 calcium-binding protein A6; SOD3, superoxide dismutase 3; iTRAQ, isobaric tags for relative and absolute quantitation.](ol-16-02-2355-g01){#f2-ol-0-0-8941}

![Expression of S100A6 and SOD3 proteins in the mesenchyma of NGM and GMAH tissues. (A) The expression of S100A6 and SOD3 proteins in NGM and GMAH mesenchymal tissues were detected by western blot analysis. Expression levels of proteins in two tissues were determined by densitometric analysis (n=3; \*P\<0.01 vs. NGM). (B) Immunohistochemistry revealed the expression of the S100A6 protein in NGM and GMAH mesenchyma. Original magnification, ×10 (left) and ×40 (right). (C) Immunohistochemistry revealed the expression of the SOD3 protein in NGM and GMAH mesenchyma. Original magnification, ×10 (left) and ×40 (right). S100A6, S100 calcium-binding protein A6; SOD3, superoxide dismutase 3; NGM, normal gastric mucosa; GMAH, gastric mucosal atypical hyperplasia.](ol-16-02-2355-g02){#f3-ol-0-0-8941}

![KEGG signal pathway analysis of differentially expressed proteins analyzed using Cytoscape software. (A) The signal pathway involved in the proteins that are upregulated in GMAH compared with NGM tissues. (B) The signal pathway involved in the proteins that are downregulated in GMAH compared with NGM tissues. KEGG, Kyoto Encyclopedia of Genes and Genomes; NGM, normal gastric mucosa; GMAH, gastric mucosal atypical hyperplasia; MAPK, mitogen-activated protein kinase; RIG, retinoic acid-induced gene; HTLV, human T-lymphotropic virus; NOD, nucleotide-binding oligomerization domain.](ol-16-02-2355-g03){#f4-ol-0-0-8941}

###### 

Clinicopathological features of patients with gastric cancer.

  No.   Sex      Age, years   Differentiation   Tumor stage ([@b8-ol-0-0-8941])   Date of collection
  ----- -------- ------------ ----------------- --------------------------------- --------------------
  1     Male     49           Moderate          II                                September 2016
  2     Female   64           Poor              IV                                September 2016
  3     Female   69           Poor              IV                                September 2016
  4     Male     62           Poor              II                                October 2016
  5     Male     44           Moderate          II                                October 2016
  6     Male     60           Poor              II                                November 2016
  7     Male     53           Poor              II                                November 2016
  8     Female   40           Poor              III                               November 2016
  9     Male     67           Poor              II                                December 2016
  10    Female   81           Poor              II                                December 2016
  11    Female   47           High              II                                January 2017
  12    Male     63           Poor              II                                February 2017
  13    Male     52           Poor              IV                                March 2017
  14    Male     46           Moderate          II                                March 2017
  15    Male     51           Poor              II                                March 2017
  16    Male     60           Moderate          II                                March 2017
  17    Female   66           Poor              III                               April 2017
  18    Male     67           Poor              II                                April 2017
  19    Female   68           Poor              II                                May 2017
  20    Female   62           Poor              III                               June 2017

###### 

Differentially expressed proteins between the NGM and GMAH mesenchyma.

  No.   Accession no.   Protein name                                          GMAH vs. NGM
  ----- --------------- ----------------------------------------------------- --------------
  1     IPI00872780.1   ANXA4, annexin A4                                     ↑1.5704
  2     IPI00027230.3   HSP90B1, endoplasmin precursor                        ↑1.5704
  3     IPI00024920.1   ATP5D, ATP synthase subunit δ                         ↑1.5704
  4     IPI00013508.5   ACTN1, α-actinin-1                                    ↑1.5848
  5     IPI00216135.1   TPM1, isoform 3 of tropomyosin α-1 chain              ↑1.5995
  6     IPI00788802.1   TKT, transketolase variant                            ↑1.6292
  7     IPI00647915.1   TAGLN2, 24 kDa protein                                ↑1.6292
  8     IPI00025874.2   RPN1                                                  ↑1.6750
  9     IPI00020599.1   CALR, calreticulin precursor                          ↑1.7062
  10    IPI00219219.3   LGALS1, galectin-1                                    ↑1.7379
  11    IPI00218918.5   ANXA1, annexin A1                                     ↑1.7379
  12    IPI00218733.6   SOD1, superoxide dismutase                            ↑1.7864
  13    IPI00010796.1   P4HB, protein disulfide-isomerase precursor           ↑1.7864
  14    IPI00414283.5   FN1, fibronectin 1 isoform 4 preproprotein            ↑1.8198
  15    IPI00298547.3   PARK7, protein DJ-1                                   ↑1.8198
  16    IPI00794402.1   ARHGDIA, 28 kDa protein                               ↑1.8365
  17    IPI00219446.5   PEBP1, phosphatidylethanolamine-binding protein 1     ↑1.8879
  18    IPI00553177.1   SERPINA1                                              ↑1.9771
  19    IPI00029623.1   PSMA6, proteasome subunit α type-6                    ↑1.9952
  20    IPI00026314.1   GSN, isoform 1 of gelsolin precursor                  ↑2.0137
  21    IPI00479186.5   PKM2                                                  ↑2.0700
  22    IPI00033494.3   MRLC2, myosin regulatory light chain                  ↑2.0700
  23    IPI00418471.6   VIM, vimentin                                         ↑2.2492
  24    IPI00169383.3   PGK1, phosphoglycerate kinase 1                       ↑2.2492
  25    IPI00396321.1   LRRC59, leucine-rich repeat-containing protein 59     ↑2.2696
  26    IPI00027947.6   CTRL, chymotrypsin-like protease                      ↑2.2696
  27    IPI00884105.1   LAMP1                                                 ↑2.3337
  28    IPI00789605.1   MYL6                                                  ↑2.3770
  29    IPI00219018.7   GAPDH, glyceraldehyde-3-phosphate dehydrogenase       ↑2.3770
  30    IPI00021405.3   LMNA, isoform A of lamin-A/C                          ↑2.3770
  31    IPI00654755.3   HBB, hemoglobin subunit β                             ↑2.3987
  32    IPI00024284.4   HSPG2                                                 ↑2.4661
  33    IPI00020987.1   PRELP, prolargin precursor                            ↑2.4888
  34    IPI00871843.1   TGM2, 81 kDa protein                                  ↑2.5349
  35    IPI00418169.3   ANXA2, annexin A2 isoform 1                           ↑2.5349
  36    IPI00291136.4   COL6A1, collagen α-1(VI) chain                        ↑2.5349
  37    IPI00009771.6   LMNB2, lamin-B2                                       ↑2.5349
  38    IPI00742225.1   LOC646483, DNA-binding protein TAXREB107 isoform 1    ↑2.5589
  39    IPI00297084.7   DDOST                                                 ↑2.6062
  40    IPI00216138.6   TAGLN, transgelin                                     ↑2.6546
  41    IPI00025252.1   PDIA3, protein disulfide-isomerase A3                 ↑2.6788
  42    IPI00414676.6   HSP90AB1, heat-shock protein HSP 90-β                 ↑2.8843
  43    IPI00009904.1   PDIA4, protein disulfide-isomerase A4                 ↑2.8843
  44    IPI00382696.1   FLNB, isoform 2 of filamin-B                          ↑2.9104
  45    IPI00022200.2   COL6A3, α3 type VI collagen isoform 1                 ↑2.9922
  46    IPI00479145.2   KRT19, type I cytoskeletal 19                         ↑3.0202
  47    IPI00792191.1   GATM, glycine amidinotransferase                      ↑3.0479
  48    IPI00872814.1   Uncharacterized protein MSN (fragment)                ↑3.1328
  49    IPI00008274.7   CAP1, adenylate cyclase-associated protein 1          ↑3.1328
  50    IPI00887241.1   LOC650788, 40S ribosomal protein S28                  ↑3.2206
  51    IPI00829626.1   IGL@ protein                                          ↑3.2206
  52    IPI00220278.5   MYL9, myosin regulatory light chain 2                 ↑3.2206
  53    IPI00021766.5   RTN4, isoform 1 of reticulon-4                        ↑3.2510
  54    IPI00871932.1   SPTBN1, 276 kDa protein                               ↑3.3422
  55    IPI00465431.7   LGALS3, galectin-3                                    ↑3.3422
  56    IPI00333541.6   FLNA, filamin-A                                       ↑3.4674
  57    IPI00221226.7   ANXA6, annexin A6                                     ↑3.5323
  58    IPI00025465.1   OGN, mimecan precursor                                ↑3.5323
  59    IPI00013296.3   RPS18                                                 ↑3.5651
  60    IPI00299145.9   KRT6C, type II cytoskeletal 6C                        ↑3.7665
  61    IPI00515087.2   CTRB2, chymotrypsinogen B2                            ↑4.0933
  62    IPI00450768.7   KRT17, type I cytoskeletal 17                         ↑4.0933
  63    IPI00745872.2   ALB, isoform 1 of serum albumin precursor             ↑4.2070
  64    IPI00218914.5   ALDH1A1, retinal dehydrogenase 1                      ↑4.8309
  65    IPI00027350.3   PRDX2, peroxiredoxin-2                                ↑4.8309
  66    IPI00000874.1   PRDX1, peroxiredoxin-1                                ↑4.8309
  67    IPI00887678.1   LOC654188, peptidylprolyl isomerase A-like            ↑5.1520
  68    IPI00848226.1   GNB2L1                                                ↑5.3937
  69    IPI00883857.1   HNRNPU                                                ↑5.4945
  70    IPI00744153.2   Uncharacterized protein GCG                           ↑5.8072
  71    IPI00020986.2   LUM, lumican precursor                                ↑5.8617
  72    IPI00010471.5   LCP1, plastin-2                                       ↑5.9172
  73    IPI00028030.3   COMP, cartilage oligomeric matrix protein             ↑6.1958
  74    IPI00220271.3   AKR1A1, alcohol dehydrogenase                         ↑6.6050
  75    IPI00000690.1   AIFM1, isoform 1 of apoptosis-inducing factor 1       ↑6.6050
  76    IPI00296099.6   THBS1, thrombospondin-1 precursor                     ↑6.7935
  77    IPI00798430.1   TF, transferrin variant                               ↑7.0472
  78    IPI00410241.2   POSTN, periostin, osteoblast specific factor          ↑7.1124
  79    IPI00646304.4   PPIB, peptidylprolyl isomerase B precursor            ↑7.3801
  80    IPI00022391.1   APCS, serum amyloid P-component precursor             ↑7.3801
  81    IPI00021263.3   YWHAZ, 14-3-3 protein ζ/δ                             ↑7.3801
  82    IPI00607708.3   LDHA, isoform 2 of L-lactate dehydrogenase A chain    ↑8.3963
  83    IPI00749250.2   ACTR2 45 kDa protein                                  ↑8.7108
  84    IPI00004457.3   AOC3, membrane copper amine oxidase                   ↑10.2775
  85    IPI00027463.1   S100A6, protein S100 A6                               ↑10.3734
  86    IPI00215719.6   RPL18, 60S ribosomal protein L18                      ↑10.7643
  87    IPI00014361.1   TSTA3, GDP-L-fucose synthetase                        ↑11.3766
  88    IPI00012750.3   RPS25, 40S ribosomal protein S25                      ↑12.2399
  89    IPI00010414.4   PDLIM1, PDZ and LIM domain protein 1                  ↑12.2399
  90    IPI00744375.1   HLA-C                                                 ↑12.7065
  91    IPI00399007.5   IGHG2                                                 ↑13.5501
  92    IPI00291006.1   MDH2                                                  ↑14.4509
  93    IPI00807428.1   Putative uncharacterized protein                      ↑16.8919
  94    IPI00738499.2   FTL, ferritin light chain                             ↑20.8768
  95    IPI00215965.2   HNRNPA1                                               ↑26.5252
  96    IPI00790262.1   TTLL3                                                 ↑27.0270
  97    IPI00550991.3   SERPINA3                                              ↑32.4675
  98    IPI00015911.1   DLD, dihydrolipoyl dehydrogenase                      ↑38.7597
  99    IPI00060715.1   KCTD12                                                ↑39.0625
  100   IPI00465084.6   DES, desmin                                           ↓0.0406
  101   IPI00396378.3   HNRNPA2B1                                             ↓0.0855
  102   IPI00514669.1   SH3BGRL                                               ↓0.0991
  103   IPI00027827.2   SOD3                                                  ↓0.1057
  104   IPI00025476.1   AMY1B, pancreatic α-amylase precursor                 ↓0.1086
  105   IPI00473011.3   HBD, hemoglobin subunit δ                             ↓0.1127
  106   IPI00847342.1   KRT7, keratin 7                                       ↓0.1148
  107   IPI00877792.1   FGG, 50 kDa protein                                   ↓0.1259
  108   IPI00815665.1   PRSS1, PRSS1 protein                                  ↓0.1259
  109   IPI00011654.2   TUBB, tubulin β chain                                 ↓0.1306
  110   IPI00021885.1   FGA, isoform 1 of fibrinogen α chain precursor        ↓0.1318
  111   IPI00009634.1   SQRDL                                                 ↓0.1803
  112   IPI00478003.1   A2M, α~2~-macroglobulin precursor                     ↓0.2014
  113   IPI00867509.1   CORO1C, coronin-1C_i3 protein                         ↓0.2291
  114   IPI00642455.2   THBS2, thrombospondin 2                               ↓0.2291
  115   IPI00000105.4   MVP, major vault protein                              ↓0.2377
  116   IPI00027720.1   PNLIP, pancreatic triacylglycerol lipase precursor    ↓0.2421
  117   IPI00140420.4   SND1                                                  ↓0.2805
  118   IPI00515061.3   HIST1H2BJ, histone H2B type 1-J                       ↓0.2884
  119   IPI00410714.5   HBA1, hemoglobin subunit α                            ↓0.2911
  120   IPI00295663.1   ELA3A, elastase-3A precursor                          ↓0.2965
  121   IPI00298497.3   FGB, fibrinogen β chain precursor                     ↓0.2992
  122   IPI00759832.1   YWHAB, isoform short of 14-3-3 protein β/α            ↓0.3020
  123   IPI00003527.5   SLC9A3R1                                              ↓0.3221
  124   IPI00788782.1   ATP1A3, Na^+^/K^+^-ATPase α3 subunit variant          ↓0.3404
  125   IPI00028908.3   NID2, nidogen-2 precursor                             ↓0.3532
  126   IPI00186290.6   EEF2, elongation factor 2                             ↓0.3698
  127   IPI00010779.4   TPM4, isoform 1 of tropomyosin α-4 chain              ↓0.3767
  128   IPI00873444.1   UBC, RPS27A 79 kDa protein                            ↓0.3837
  129   IPI00156689.3   VAT1                                                  ↓0.3945
  130   IPI00178926.2   IGJ, immunoglobulin J chain                           ↓0.3981
  131   IPI00021827.3   DEFA3, neutrophil defensin 3 precursor                ↓0.3981
  132   IPI00337741.4   APEH, acylamino-acid-releasing enzyme                 ↓0.4055
  133   IPI00292530.1   ITIH1, inter-α-trypsin inhibitor heavy chain H1       ↓0.4169
  134   IPI00031522.2   HADHA, trifunctional enzyme subunit α                 ↓0.4207
  135   IPI00426051.3   Putative uncharacterized protein DKFZp686C15213       ↓0.4246
  136   IPI00009027.1   REG1A, lithostathine-1-α precursor                    ↓0.4246
  137   IPI00300725.7   KRT6A, type II cytoskeletal 6A                        ↓0.4365
  138   IPI00555744.6   RPL14 protein                                         ↓0.4529
  139   IPI00465361.4   RPL13, 60S ribosomal protein L13                      ↓0.4571
  140   IPI00843810.2   CEL, carboxyl ester lipase                            ↓0.4699
  141   IPI00024933.3   RPL12, 60S ribosomal protein L12                      ↓0.4966
  142   IPI00845263.1   FN1, fibronectin 1 isoform 2 preproprotein            ↓0.5012
  143   IPI00449920.1   IGHA1, highly similar to Ig α-1 chain C region        ↓0.5105
  144   IPI00289862.3   SCRN1, secernin-1                                     ↓0.5105
  145   IPI00002745.1   CTSZ, cathepsin Z precursor                           ↓0.5152
  146   IPI00005924.4   PNLIPRP2, pancreatic lipase-related protein 2         ↓0.5297
  147   IPI00873137.1   COL1A2, 130 kDa protein                               ↓0.5346
  148   IPI00783512.1   Reversed PTPRN2 110 kDa protein                       ↓0.5346
  149   IPI00552768.1   TXN, thioredoxin                                      ↓0.5346
  150   IPI00294380.5   PCK2                                                  ↓0.5395
  151   IPI00007765.5   HSPA9, stress-70 protein, mitochondrial precursor     ↓0.5445
  152   IPI00472724.1   EEF1AL3, elongation factor 1-α-like 3                 ↓0.5495
  153   IPI00297646.4   COL1A1, collagen α-1(I) chain                         ↓0.5495
  154   IPI00307162.2   VCL, isoform 2 of vinculin                            ↓0.5649
  155   IPI00009826.2   CPB1, carboxypeptidase B precursor                    ↓0.5649
  156   IPI00003362.2   HSPA5 protein                                         ↓0.5649
  157   IPI00305461.2   ITIH2, inter-α-trypsin inhibitor heavy chain H2       ↓0.5754
  158   IPI00027497.5   GPI, glucose-6-phosphate isomerase                    ↓0.5971
  159   IPI00061005.4   ERP27, endoplasmic reticulum-resident protein ERp27   ↓0.6138
  160   IPI00298994.6   TLN1, talin-1                                         ↓0.6194
  161   IPI00026302.3   RPL31, 60S ribosomal protein L31                      ↓0.6194
  162   IPI00856098.1   p180/ribosome receptor                                ↓0.6252
  163   IPI00216134.3   TPM1, tropomyosin 1 α chain isoform 7                 ↓0.6252
  164   IPI00009823.3   CPA1, carboxypeptidase A1 precursor                   ↓0.6486
  165   IPI00009867.3   KRT5, type II cytoskeletal 5                          ↓0.6607

S100A6 and SOD3 are highlighted in bold. NGM, normal gastric mucosa; GMAH, gastric mucosal atypical hyperplasia; ↑, upregulation of expression in GMAH mesenchyma; ↓, downregulation of expression in GMAH mesenchyma.

###### 

Expression levels of S100A6 and SOD3 proteins in the NGM and GMAH tissues.

                Score             
  -------- ---- ------- ----- --- ----------------------------------------------------
  SOD3                            
    NGM    20     8       8   4   60.00
    GMAH   20   14        4   2   30.00^[a](#tfn2-ol-0-0-8941){ref-type="table-fn"}^
  S100A6                          
    NGM    20   13        4   3   35.00
    GMAH   20     7     11    2   65.00^[a](#tfn2-ol-0-0-8941){ref-type="table-fn"}^

P\<0.05, GMAH vs. NGM tissues. SOD3, superoxide dismutase 3; S100A6, S100 calcium-binding protein A6; NGM, normal gastric mucosa; GMAH, gastric mucosal atypical hyperplasia.
